These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 30942881)
1. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. Morrow M; MaWhinney S; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR J Infect Dis; 2019 Jul; 220(4):635-642. PubMed ID: 30942881 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238 [TBL] [Abstract][Full Text] [Related]
3. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. Odayar J; Orrell C; Phillips TK; Hu NC; Kabanda S; Malaba TR; Allerton J; Wiesner L; Hsiao NY; Castillo-Mancilla J; Lesosky M; Myer L Clin Infect Dis; 2022 Sep; 75(5):761-767. PubMed ID: 34979553 [TBL] [Abstract][Full Text] [Related]
4. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768 [TBL] [Abstract][Full Text] [Related]
5. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. Jennings L; Robbins RN; Nguyen N; Ferraris C; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Remien RH; Orrell C; AIDS; 2022 Jun; 36(7):933-940. PubMed ID: 35131960 [TBL] [Abstract][Full Text] [Related]
6. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. Castillo-Mancilla JR; Edwards JA; Brijkumar J; Moosa MY; Zhao Y; Ofotokun I; Johnson BA; Lee MH; Pillay S; Pillay M; Moodley P; Kuritzkes DR; Sunpath H; Bushman LR; Ellison L; Anderson PL; Marconi VC J Int AIDS Soc; 2021 Dec; 24(12):e25849. PubMed ID: 34910844 [TBL] [Abstract][Full Text] [Related]
8. Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy. Dorward J; Govender K; Moodley P; Lessells R; Samsunder N; Sookrajh Y; Fanshawe TR; Turner PJ; Butler CC; Drain PK; Hayward GN; Garrett N AIDS; 2024 Apr; 38(5):697-702. PubMed ID: 38126342 [TBL] [Abstract][Full Text] [Related]
9. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682 [TBL] [Abstract][Full Text] [Related]
10. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa. Singh Y; Castillo-Mancilla J; Madimabe R; Jennings L; Ferraris CM; Robbins RN; Anderson PL; Remien RH; Orrell C AIDS Res Ther; 2023 Sep; 20(1):67. PubMed ID: 37705102 [TBL] [Abstract][Full Text] [Related]
11. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. Coyle RP; Schneck CD; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL; Castillo-Mancilla JR AIDS Behav; 2019 Dec; 23(12):3493-3502. PubMed ID: 30798457 [TBL] [Abstract][Full Text] [Related]
12. Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. Saderup AM; Morrow M; Libby AM; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR Pharmacotherapy; 2021 Mar; 41(3):291-298. PubMed ID: 33594735 [TBL] [Abstract][Full Text] [Related]
13. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review. Wu L; Niu X; Brunelli MK; Mugwanya KK Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667 [TBL] [Abstract][Full Text] [Related]
14. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282 [TBL] [Abstract][Full Text] [Related]
15. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288 [TBL] [Abstract][Full Text] [Related]
16. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. Morrow M; MaWhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR AIDS; 2021 Oct; 35(12):1949-1956. PubMed ID: 34127580 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. Coyle RP; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR J Antimicrob Chemother; 2020 Jun; 75(6):1591-1598. PubMed ID: 32211787 [TBL] [Abstract][Full Text] [Related]
18. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM; J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433 [TBL] [Abstract][Full Text] [Related]
19. Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens. Coyle RP; Morrow M; MaWhinney S; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR Pharmacotherapy; 2022 Aug; 42(8):641-650. PubMed ID: 35707973 [TBL] [Abstract][Full Text] [Related]
20. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG; J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]